Popular Articles
Teeth Whitening Products

Ardea Biosciences Announces Positive Interim Phase 2a Results For Lead Gout Drug, RDEA594
Ardea Biosciences, Inc. (Nasdaq:RDEA) announced positive interim results from an ongoing Phase 2a, proof-of-concept study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout, as well as additional positive results from completed Phase 1 studies of RDEA594 in normal, healthy volunteers. The Phase 1 results, along with additional preclinical data, were presented at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism (EULAR) in Copenhagen, Denmark.
generic viagra online
17 Of America's Most Promising Scientists Selected As 2009 Pew Scholars In The Biomedical Sciences
The Pew Charitable Trusts today named 17 early-career scientists as Pew Scholars in the Biomedical Sciences. Scholars receive a $240,000 award over four years to help support their work, which this year includes research related to cancer, Parkinson"s disease, birth defects and epilepsy. The Scholars also gain inclusion into a select community of scientists that includes Nobel Prize winners, MacArthur Fellows and recipients of the Albert Lasker Medical Research Award.
News of the day
Test Detects Molecular Marker Of Aging In Humans
In 2004, researchers at the University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center announced a crucial discovery in the understanding of cellular aging. They found that as cells and tissues age, the expression of a key protein, called p16INK4a, dramatically increases in most mammalian organs. Because p16INK4a is a tumor suppressor protein, cancer researchers are interested in its role in cellular aging and cancer prevention.
Diagnostics

New System May Allow Xenon Use To Protect Brain In Critically Ill Newborns

Breathing xenon gas can help protect the infant brain from damage caused by oxygen deprivation, but the xenon"s high cost and scarcity has precluded its widespread use. A newly developed "closed circuit system" may make xenon feasible, safe, and cost efficient for use in protecting the brains of critically ill infants, according to a study in the August issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS). The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals, and institutions in medicine, nursing, allied health, pharmacy and the pharmaceutical industry. Led by Dr. John Dingley of University of Wales, Swansea, a U.K. research team introduces a new method of giving xenon to newborn infants with birth defects and other life-threatening conditions requiring surgery and anesthesia. The usual reason for newborns to undergo surgery is a critical problem with the infants" breathing or circulation that prevents their tissues from getting enough oxygen. This lack of oxygen is particularly damaging to the brain, with long-term consequences for the child. Although it is chemically considered an inert gas, xenon has profound biological effects in high concentrations, it can induce unconsciousness. For several years, researchers have known that xenon provides protection against some forms of low-oxygen injury to the brain. However, because xenon is extremely expensive, its use is currently limited to a few experimental centers. Closed-Circuit System Allows Xenon to Be Given for $2 per Hour To address this problem, Dr. Dingley and colleagues designed a closed-circuit xenon delivery system. The system takes advantage of the fact that uptake of xenon by the lung is very low when a given amount of xenon is breathed in, almost all of it is breathed out. The new system, fitted to a conventional newborn ventilator, essentially recaptures the exhaled xenon so that the infant can re-breathe it. The system adds precise amounts of oxygen and other gases as needed. The researchers tested their closed-circuit xenon delivery system on newborn pigs. They found that they could precisely control the depth of anesthesia, while delivering exactly the right amount of oxygen. The piglets had stable vital signs and recovered without any complications. The xenon system could be used with our without cooling of body temperature (hypothermia) previously the only technique known to protect the brain in infants with low-oxygen injury. Using the closed circuit system, the researchers estimate that xenon could be used for surgery in critically ill newborns for as little as $2 per hour. This would allow "responsible use of a restricted global xenon supply in the maximum number of clinical cases per year," according to Dr. Dingley and colleagues. They believe that the simple design and operational cost of the system should make the delivery of xenon once considered prohibitively expensive for routine medical use safe and inexpensive for newborns requiring surgery and anesthesia for life-threatening birth defects. About the IARS The International Anesthesia Research Society is a nonpolitical, not-for-profit medical society founded in 1922 to encourage, stimulate, and fund ongoing anesthesia-related research and projects that will enhance and advance the anesthesiology specialty. The IARS has a worldwide membership of 15,000 physicians, physician residents, and others with doctoral degrees, as well as health professionals in anesthesia-related practice. In additional to publishing the monthly scientific journal Anesthesia & Analgesia, the IARS sponsors an annual clinical and scientific meeting, funds anesthesia-related research, and sponsors the SAFEKIDS research initiative in conjunction with the FDA. IARS


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):